Navigation Links
Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development
Date:7/3/2008

IRVINE, Calif., July 3 /PRNewswire/ -- Antigen Discovery Inc. ("ADI", formerly ImmPORT Therapeutics Inc.), a leader in high throughput antigen/biomarker discovery using advanced genomics and proteomics tools, announced today that the Company was awarded a Phase II SBIR from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Center for Research Resources (NCRR). The $3 million grant will fund efforts to further develop ADI's protein microarray based serodiagnostic platform for applications in biodefense and emerging infectious diseases. ADI will collaborate with investigators at the Proteomics Core facility of the Pacific Southwest Regional Center of Excellence (PSW RCE), located at the University of California, Irvine.

"The major bottleneck that limits the translation of readily available genomic information into the development of next generation diagnostics, vaccines and therapeutics, is the continued lack of effective antigen and biomarker discovery tools," said Dr. Xiaowu Liang, CEO of ADI. "We are grateful that the SBIR program continues to fund ADI and our UCI collaborators in the further development of this exciting new technology platform that truly revolutionizes the screening and detection of disease markers."

"The focus of this grant is to commercialize some of the broad applications of the platform technology that were developed during previous funding phases. The establishment of a Good Manufactuing Practices (GMP) facility, and a Clinical Research Lab will enable us to offer diagnostic products and services to physicians, point of care facilities, developers of novel vaccines, and pharmaceutical researchers," added Dr. Huw Davies, the Principal Investigator on the SBIR grant. "By using our novel protein array systems and statistical algorithms, we can rapidly discover antigen sets that will provide serological tests that discriminate between different infections, or even between different stages of the same infection."

About Antigen Discovery Inc.

Antigen Discovery Inc. (formerly ImmPORT Therapeutics Inc.) is a privately held biotech company with innovative technologies that offer unprecedented advantages for the rapid development of safer and more effective vaccines and diagnostic products. The Company's high throughput proteome microarray chip fabrication and screening platform provides an order of magnitude of improvement over current antigen/biomarker discovery technologies. The technology also has potential applications in the identification of markers for autoimmune disease and cancer.


'/>"/>
SOURCE Antigen Discovery Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
2. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
3. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
4. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
5. Discovery by UC Riverside physicists could enable development of faster computers
6. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
7. Oncomine(TM) Again Key to Prostate Cancer Discovery
8. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
9. Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
10. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
11. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... SAN DIEGO, Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: ... year ended December 31, 2015. --> ... reported a net loss of $29.3 million, or $0.34 loss per ... loss per share for the same period in 2014. For the ... of $88.9 million, or $1.05 loss per share, as compared to ...
(Date:2/11/2016)... Germany and GERMANTOWN, Maryland ... QGEN ; Frankfurt Prime Standard: QIA) today announced the ... Panels for gene expression profiling, expanding QIAGEN,s portfolio of ... panels enable researchers to select from over 20,000 human ... discover interactions between genes, cellular phenotypes and disease processes. ...
(Date:2/11/2016)... -- Spectra BioPharma Selling Solutions (Spectra) is a new ... the experience, expertise, operational delivery and customer focus ... Created in concert with industry leading commercial experts, ... tactical needs of its clients by providing value-based ... and non-personal promotion. --> ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... focused on the development and manufacture of biopharmaceuticals and therapeutics, announces an ... the 2016 BioProcess International Awards – Recognizing Excellence in the People, Organizations ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
(Date:2/1/2016)... , February 1, 2016 Rising ... to drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new ... market size through 2020   ... coupled with new technological advancements to drive global touchfree ...
(Date:1/25/2016)... BLUE BELL, Pa. , Jan. 25, 2016   Unisys ... facial recognition system at John F. Kennedy (JFK) International Airport, ... and Border Protection (CBP) identify imposters attempting to enter ... or do not belong to them. pilot testing ... rolled out initially at three terminals at JFK during January 2016. ...
Breaking Biology News(10 mins):